Difference between revisions of "BL22 immunotoxin (CAT-3888)"
Jump to navigation
Jump to search
m (Jwarner moved page CAT-3888 (BL22) to BL22 immunotoxin (CAT-3888)) |
m |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.] | + | Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death. |
| + | |||
| + | Although not confirmed as no longer in development, this drug appears to have been superseded by the more potent and less toxic [[Moxetumomab pasudotox (HA22)]]. The company was also acquired.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref> | ||
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 8: | Line 10: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| − | == | + | ==Preliminary data== |
| − | |||
| − | |||
| − | |||
| − | == | + | ===[[Hairy cell leukemia]]=== |
| − | + | # '''Abstract:''' R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=3999 Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia.] 2004 ASCO Annual Meeting abstract 6624. | |
| + | # '''Abstract:''' R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34304 Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia.] 2007 ASCO Annual Meeting abstract 7095. | ||
| + | # Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [http://jco.ascopubs.org/content/27/18/2983.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/19414673 PubMed] | ||
==References== | ==References== | ||
Revision as of 01:44, 8 September 2015
In clinical trials. Also known as GCR-3888. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
General information
Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
Although not confirmed as no longer in development, this drug appears to have been superseded by the more potent and less toxic Moxetumomab pasudotox (HA22). The company was also acquired.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Preliminary data
Hairy cell leukemia
- Abstract: R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, I. Pastan. Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia. 2004 ASCO Annual Meeting abstract 6624.
- Abstract: R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, I. Pastan. Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia. 2007 ASCO Annual Meeting abstract 7095.
- Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article PubMed